期刊
INTERNATIONAL IMMUNOPHARMACOLOGY
卷 114, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.intimp.2022.109463
关键词
Tumor targeted delivery; MIP; Bacterial immunotherapy; Paclitaxel nanoparticles; Chitosan nanoparticles
A tumor targeted delivery system was developed using chitosan nanoparticles loaded with MIP adjuvants, which showed preferential accumulation within the tumor microenvironment. The MIP nano-formulations significantly reduced tumor volume and increased the frequency of activated immune cells in the TME. Combination therapy with MIP nano-formulation and Paclitaxel further decreased tumor volume.
Targeting immunotherapeutics inside the tumor microenvironment (TME) with intact biological activity remains a pressing issue. Mycobacterium indicus pranii (MIP), an approved adjuvant therapy for leprosy has exhibited promising results in clinical trials of lung (NSCLC) and bladder cancer. Whole MIP as well as its cell wall fraction have shown tumor growth suppression and enhanced survival in mice model of melanoma, when administered peritumorally. Clinically, peritumoral delivery remains a procedural limitation. In this study, a tumor targeted delivery system was designed, where chitosan nanoparticles loaded with MIP adjuvants, when administered intravenously showed preferential accumulation within the TME, exploiting the principle of enhanced permeability and retention effect. Bio-distribution studies revealed their highest concentration inside the tumor after 6 h of administration. Interestingly, MIP adjuvant nano-formulations significantly reduced the tumor volume in the treated groups and increased the frequency of activated immune cells inside the TME. For chemoimmunotherapeutics studies, MIP nano-formulation was combined with standard dosage regimen of Paclitaxel. Combined therapy exhibited a further reduction in tumor volume relative to either of the MIP nano formulations. From this study a three-pronged strategy emerged as the underlying mechanism; chitosan and Paclitaxel have shown direct role in tumor cell death and the MIP nano-formulation activates the tumor residing immune cells which ultimately leads to the reduced tumor growth.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据